Stereotactic Radiosurgery for Intracranial Ependymomas: An International Multicenter Study
Language English Country United States Media print
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
29608701
DOI
10.1093/neuros/nyy082
PII: 4955825
Knihovny.cz E-resources
- MeSH
- Child MeSH
- Progression-Free Survival MeSH
- Adult MeSH
- Ependymoma mortality surgery MeSH
- Combined Modality Therapy methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local mortality surgery MeSH
- Adolescent MeSH
- Young Adult MeSH
- Brain Neoplasms mortality surgery MeSH
- Child, Preschool MeSH
- Disease Progression MeSH
- Radiosurgery adverse effects methods mortality MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Stereotactic radiosurgery (SRS) is a potentially important option for intracranial ependymoma patients. OBJECTIVE: To analyze the outcomes of intracranial ependymoma patients who underwent SRS as a part of multimodality management. METHODS: Seven centers participating in the International Gamma Knife Research Foundation identified 89 intracranial ependymoma patients who underwent SRS (113 tumors). The median patient age was 16.3 yr (2.9-80). All patients underwent previous surgical resection and radiation therapy (RT) of their ependymomas and 40 underwent previous chemotherapy. Grade 2 ependymomas were present in 42 patients (52 tumors) and grade 3 ependymomas in 48 patients (61 tumors). The median tumor volume was 2.2 cc (0.03-36.8) and the median margin dose was 15 Gy (9-24). RESULTS: Forty-seven (53%) patients were alive and 42 (47%) patients died at the last follow-up. The overall survival after SRS was 86% at 1 yr, 50% at 3 yr, and 44% at 5 yr. Smaller total tumor volume was associated with longer overall survival (P = .006). Twenty-two patients (grade 2: n = 9, grade 3: n = 13) developed additional recurrent ependymomas in the craniospinal axis. The progression-free survival after SRS was 71% at 1 yr, 56% at 3 yr, and 48% at 5 yr. Adult age, female sex, and smaller tumor volume indicated significantly better progression-free survival. Symptomatic adverse radiation effects were seen in 7 patients (8%). CONCLUSION: SRS provides another management option for residual or recurrent progressive intracranial ependymoma patients who have failed initial surgery and RT.
Department of Neurosurgery Cleveland Clinic Foundation Cleveland Ohio
Department of Neurosurgery Taipei Veteran General Hospital Taipei Taiwan
Department of Neurosurgery University of Virginia Charlottesville Virginia
Division of Neurosurgery Université de Sherbrooke Centre de Recherche du CHUS Sherbrooke Canada
Section of Neurosurgery University of Manitoba Canada
Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech
References provided by Crossref.org
